J. Cortés

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Hope S. Rugo, A. Bardia, F. Marmé et al. · Annals of Oncology · 2022 · 57 citations · Full text

Medicine, Oncology, Pharmacology +12

214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study

P. Schmid, J. Cortés, F. Marmé et al. · Annals of Oncology · 2022 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17

LBA23 ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria

J. De la Haba Rodriguez, J. Cortés, Serena Di Cosimo et al. · Annals of Oncology · 2024 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17

LBA4 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study

P. Schmid, J. Cortés, R. Dent et al. · Annals of Oncology · 2024 · 14 citations · Full text

Medicine, Oncology, Pharmacotherapy +16